T he Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study was a randomized clinical study that compared low-molecular-weight heparin (LMWH) and aspirin in patients with acute ischemic stroke and large artery occlusive disease (LAOD). 1 The results did not support a significant benefit of LMWH over aspirin in the primary outcome measure (Barthel Index). 1 Previous studies have suggested that anticoagulation may have efficacy in certain subgroups of patients with ischemic stroke such as those with large artery disease, 2 severe stenosis, 3 and vertebrobasilar disease. [3] [4] [5] Most of these studies were performed among whites, but in Asians, atherosclerosis develops frequently in the intracranial arteries 6 -9 and the relation between acute anticoagulation and ischemic stroke with LAOD in different subgroups of Asian populations remains to be elucidated. Therefore, the aim of the analysis presented here was to compare the efficacy of LMWH with aspirin in selected subgroups within the FISS-tris study.
Subjects and Methods
The design and results of the FISS-tris study have been published. 1 In brief, the study was a prospective multicenter, randomized clinical trial conducted at multiple trial sites in Hong Kong and Singapore with ethics committee approval. It was designed to compare LMWH with aspirin for the early treatment of patients with LAOD and acute ischemic stroke. Patients were treated with either nadroparin calcium 3800 antifactor Xa IU/0.4 mL subcutaneously twice daily (LMWH group) or 160 mg aspirin once daily (aspirin group) within 48 hours after stroke onset for 10 days and subsequently 80 to 300 mg aspirin once daily for 6 months. All patients aged 18 to 90 years underwent a CT brain scan before randomization and a repeat CT was performed at Day 10 (or earlier in case of rapid and severe neurological deterioration). Vascular imaging was performed within 3 days after randomization to identify moderate or greater stenosis in the internal carotid, vertebrobasilar, middle cerebral, anterior cerebral, posterior cerebral arteries by carotid duplex scan; transcranial Doppler imaging; or MR angiography, according to previous published criteria. 10, 11 Only patients with LAOD were included in analysis. Patients with pre-existing disability defined as prestroke modified Rankin Scale score Ͼ1, and severe stroke, defined as a National Institutes of Health Stroke Scale score Ͼ22, were excluded from the study. Patients with a history of intracerebral hemorrhage, known contraindication for the use of LMWH or aspirin, on anticoagulation therapy (excluding aspirin) before the onset of stroke, with a definite indication for anticoagulation, or had sustained severe hypertension (blood pressure Ͼ220/120 mm Hg) immediately before randomization were also excluded as were patients with concomitant medical conditions such as terminal carcinoma, renal failure, cirrhosis, severe dementia or psychosis, brain tumor or other significant nonischemic brain lesion on head CT scan, atrial fibrillation on electrocardiography (past or present), chronic rheumatic heart disease or metallic heart valve, or thrombocytopenia (platelet
Ͻ100ϫ10
8 /L, if known). At 6 months after randomization, the primary end point (Barthel Index) was assessed by a clinician or a nurse blinded to the treatment allocation. Good outcome was defined as Barthel Index scores Ͼ85.
Statistical Analyses
All analyses were performed according to the intent-to-treat principle. Frequencies of good outcome between LMWH and aspirin within subgroups of baseline characteristics were compared with the 2 test. If the number in any group was Ͻ5, the Fisher exact test was performed. The median age of 68 years (range, 35-89 years) was used as a cutoff point. The effect of treatment was set as OR with 95% CI, OR Ͼ1 indicating an advantage of LMWH over aspirin. All reported probability values were 2-sided with PϽ0.05 considered significant. Analysis was carried out using SPSS 15.0 (SPSS, Inc, Chicago, IL). No adjustment of probability values was performed because of limited statistical power for subgroup analysis.
Results
Of the 603 patients with acute ischemic stroke enrolled in 11 hospitals in Hong Kong and Singapore in the FISS-tris study, 353 were confirmed with LAOD by vascular imaging (300 LMWH indicates low-molecular-weight heparin; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio. * 2 test comparing good outcome of LMWH and aspirin. †Symptomatic artery was identified by cerebral vessel evaluations including transcranial Doppler, carotid duplex, and MR angiography. ‡Combinations include internal carotid artery and middle cerebral artery, middle cerebral artery and anterior cerebral artery, posterior cerebral artery and basilar artery, posterior cerebral artery and vertebral artery, basilar artery and vertebral artery, and bilateral vertebral artery stenosis identified to be symptomatic at enrollment.
had intracranial LAOD only, 42 had both intracranial and extracranial disease, and 11 had extracranial disease only). The baseline characteristics of patients randomized to either LMWH or aspirin in the various subgroups submitted to exploratory analysis were similar (Table) .
There was significant difference in the frequency of good outcome among patients over the median age of 68 years (LMWH 65% versus aspirin 49%; OR, 1.86; 95% CI, 1.02-3.41; Pϭ0.043; Table; Figure 1) . One hundred eighteen patients were on antiplatelet therapy at the time of study entry, 96 taking aspirin, 16 taking another antiplatelet agent, and 6 taking both aspirin and another antiplatelet agent. LMWH was significantly associated with good outcome in patients without ongoing antiplatelet agents on admission (LMWH 74% versus aspirin 61%; OR, 1.85; 95% CI, 1.06 -3.21; Pϭ0.029; Table; Figure 1) . A significant benefit of LMWH was also found in patients with symptomatic stenosis in the posterior circulation (LMWH 78% versus aspirin 38%; OR, 5.76; 95% CI, 2.00 -16.56; Pϭ0.001; Table; Figure 2 ). There was no difference between LMWH and aspirin in any of the other subgroups (Table; Figures 1 and 2), including in patients with National Institutes of Health Stroke Scale 0 to 8 versus Ն9.
In the FISS-tris study, functional outcome measure at 6 months using modified Rankin Scale score 0 to 2 as a good outcome was 1 of the secondary outcomes. We performed another analysis using modified Rankin Scale as the outcome. Age Ն68 years and no antiplatelet use remained significant predictors for favorable responder to LMWH but posterior circulation stroke was no longer a favorable factor (Supplemental Material; http://stroke.ahajournals.org).
Discussion
The FISS-tris study is the only acute stroke anticoagulation study that has targeted enrollment of patients with LAOD, most of whom had intracranial atherosclerosis (ICAS). In the FISStris study, LMWH was superior to aspirin using the dichotomized modified Rankin Scale 0 to 1 outcome measure after 6 months, but no benefit was found using the Barthel Index. 1 The difference may be attributed to the relatively low sensitivity of Barthel Index as a measure for mild stroke with 71% of patients achieving a score Ͼ85 at 6 months. Nevertheless, further subgroup analysis may be justified and was performed in our study. 1, 12 In our study, for patients over the median age of 68 years, compared with aspirin, LMWH was significantly associated with a favorable outcome, which suggests that LMWH may be more effective in elderly patients. Previous studies have shown that age is an independent risk factor for ICAS and hence antithrombotic therapy could reduce the risk of recurrent stroke. [13] [14] [15] [16] [17] Studies have also reported that increasing age is associated with a high prevalence of basilar artery lesions 17, 18 ; hence, age may not only increase the severity of ICAS, but also influence the distribution of occluded vessels. Retrospective studies suggest that anticoagulation could improve the outcome in certain subgroups of patients with severe stenosis (70%-99%) or vertebrobasilar disease. 3, 5 Hence, our findings support a potential role of LMWH as an effective antithrombotic therapy in the elderly.
Our analysis showed that LMWH may be more effective in populations not taking antiplatelet agents on admission, which suggests that LMWH may be preferred for patients without prior antiplatelet medication with a lower risk of recurrent stroke compared with patients who failed antithrombotic therapy and were at extremely high rates of stroke recurrence or death. 15 By contrast, in the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) study, there was no difference of stroke recurrence between warfarin or aspirin in patients on or off antithrombotic treatment. 4 However, in the WASID study, the median time from the qualifying event to randomization was 17 days, whereas in FISS-tris, anticoagulant therapy was started within 48 hours. 1, 19 Hence, for ischemic stroke with LAOD, LMWH may improve the outcome of patients not taking antiplatelet agents more effectively than aspirin or warfarin.
Finally, a significant benefit of LMWH was found in patients with symptomatic posterior circulation stenosis, which suggests that LMWH may be efficacious in patients with posterior circulation disease. Previous retrospective studies have showed the benefit of warfarin in patients with vertebrobasilar disease, 3, 5 but in the WASID study, no significant difference was identified in the territories of symptomatic arteries between aspirin and warfarin. 4 In our study, the lack of benefit of LMWH in patients with basilar artery stenosis also suggests that the advantage in patients with posterior circulation arterial disease is not robust. Furthermore, the number of patients in this subgroup was just 72, which limits power and the wide CI also reduces the reliability of this finding.
Several studies have shown that high blood pressure and diabetes were independent risk factors for asymptomatic ICAS and the impact of hypertension may be greater than that of hyperlipidemia on patients with ICAS. 6,7,14,20 -22 However, our analysis indicates that, compared with aspirin, LMWH did not show an advantage in patients with high blood pressure. A cause for this result may be co-occurrence of cerebral small vessel disease and LAOD in patients with stroke with hypertension. 23 In the FISS-tris study, sample size was not decided on the basis of subgroup analysis, so the limitation of our study is mainly related to lower power and generalizability. Thus, our analysis should considered as exploratory or hypothesisgenerating. 24 Furthermore, the possibility remains that some groups of patients who could benefit from LMWH have been excluded from this study.
In summary, patients with LAOD, especially ICAS, are at high risk of stroke recurrence and secondary cerebrovascular events. 25, 26 Our analysis suggests that LMWH may benefit patients in several subgroups such as the elderly Ͼ68 years without ongoing antiplatelet agents and with arterial stenosis in the posterior circulation. These findings suggest that further investigation should be conducted to explore the efficacy of LMWH in these subgroups of patients with ischemic stroke due to LAOD. Tables   Table 1 Comparisons of LMWH and aspirin within specified subgroups on mRS 0-2
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